leadf
logo-loader
viewProactive Group

Shares of vTv Therapeutics plunge after late-stage trial of Alzheimer's treatment failed to meet goals

Patients 'didn't improve in cognitive or functional outcomes'

Various pills
The shares slid 72% on the trial news

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) declined after the drug company said a late-stage trial of its Alzheimer’s disease treatment didn’t meet its goals.

The stock slid 72% to US$0.92 at 10:14 a.m.

“Patients taking azeliragon compared with placebo did not improve in cognitive or functional outcomes,” the firm said in a statement yesterday after the market close.

The High Point, N.C.-based company is discontinuing current clinical studies involving treatment, it said.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ascendant Resources drill program continues looking to expand south zone at...

Ascendant Resources (TSE: AND) President and CEO Chris Buncic joined Steve Darling from Proactive with news the company's drill program continues as the look at the South Zone of the Lagoa Salgada Project in Portugal. Buncic telling Proactive they are expecting to have results from this...

28 minutes ago

2 min read